De Motu Cordis (DMC) announces plans for the next stage of development for DMC-IH1, an inhaled epinephrine drug device combination product

BRISBANE, Australia, July 17, 2024 /PRNewswire/ — De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO) partner, Catalent, at Catalent’s Boston, Morrisville and San Diego sites. These expansion…